Trial Profile
Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in ARV-naïve patients initiating Abacavir/Lamivudine plus Dolutegravir
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2014
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine/abacavir
- Indications HIV-1 infections
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms VIDEOS
- 06 Dec 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 05 Mar 2014 New trial record